Hidradenitis Suppurativa: Where We Are and Where We Are Going
Open accessThe DOI matches its Crossref record; 151 of the 152 references it cites were found in a registry or an index.
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body. It is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion of the folliculopilosebaceous unit, followed by follicular rupture and immune responses. Innate pro-inflammatory cytokines (e.g., IL-1β, and TNF-α); mediators of activated T helper (Th)1 and Th17 cells (e.g., IFN-γ, and IL-17); and effector mechanisms of neutrophilic granulocytes, macrophages, and plasma cells are involved. On the other hand, HS lesions contain anti-inflammatory mediators (e.g., IL-10) and show limited activity of Th22 cells. The inflammatory vicious circle finally results in pain, purulence, tissue destruction, and scarring. HS pathogenesis is still enigmatic, and a valid animal model for HS is currently not available. All these aspects represent a challenge for the development of therapeutic approaches, which are urgently needed for this debilitating disease. Available treatments are limited, mostly off-label, and surgical interventions are often required to achieve remission. In this paper, we provide an overview of the current knowledge surrounding HS, including the diagnosis, pathogenesis, treatments, and existing translational studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Progression leads to follicular rupture, with release of keratin, hair shaft fragments, and microbial products into the dermis [38,39].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of dermal tunnels is particularly useful in established diseases and distinguishes hidradenitis suppurativa from simple folliculitis or isolated abscesses.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In more advanced lesions, the most characteristic and frequent histological finding is the presence of epithelium-lined sinus tracts or dermal tunnels, usually associated with chronic inflammation, granulation tissue, fibrosis, and scarring [38].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ruptured follicles trigger a dense mixed inflammatory infiltrate composed of neutrophils, lymphocytes, plasma cells, macrophages, and foreign-body giant cells. These are frequently seen in early lesions.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hidradenitis suppurativa is a chronic inflammatory disease characterized by painful nodules, abscesses, scarring, and a complex molecular and cellular landscape [38].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Agus, A., Planchais, J., & Sokol, H. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.003 · Cited by 3,180 · cited 1×
“In addition, a dysregulation of tryptophan catabolism (with overactivation of the kynurenine pathway and consequent stimulation of cytokines by inflammatory cell infiltrates) and of an aryl hydrocarbon receptor (AHR) (with impaired production of bacteria-derived AHR agonists and decreased incidence of AHR ligand-produ…”
BackgroundEuropean S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Zouboulis, C. C., Desai, N., Emtestam, L., Hunger, R. E., Ioannides, D., Juhász, I., Lapins, J., Matusiak, L., Prens, E. P., Revuz, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12966 · Cited by 1,093 · cited 4×
“No unrestricted recommendation can be given for the use of conventional immunosuppressant or immunomodulatory drugs including prednisolone [103], dapsone [104], retinoids [105], and ciclosporin [106], amongst others, as there is little or conflicting evidence for their efficacy [63,98].”
BackgroundInfluentialTwo Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, A. B., Okun, M. M., Williams, D. A., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F., Gold, M. H., Forman, S. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504370 · Cited by 807
Revuz, J. E., Canoui-Poitrine, F., Wolkenstein, P., Viallette, C., Gabison, G., Pouget, F., Poli, F., Faye, O., Roujeau, J. C., Bonnelye, G., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.06.020 · Cited by 627
Sabat, R., Jemec, G. B. E., Matusiak, Ł., Kimball, A. B., Prens, E., & Wolk, K. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0149-1 · Cited by 573
Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity
Sartorius, K., Emtestam, L., Jemec, G. B. E., & Lapins, J. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09198.x · Cited by 525 · cited 3×
“Still today, the Hurley staging and the Sartorius scoring, together with HS Physician Global Assessment systems are the most commonly used assessment tools [22,23].”
BackgroundMethodZouboulis, C. C., Tzellos, T., Kyrgidis, A., Jemec, G. B. E., Bechara, F. G., Giamarellos‐Bourboulis, E. J., Ingram, J. R., Kanni, T., Karagiannidis, I., Martorell, A., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15748 · Cited by 493
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment
Saunte, D. M. L., & Jemec, G. B. E. (2017) · JAMA · doi:10.1001/jama.2017.16691 · Cited by 492 · cited 1×
“Independent of the duration and severity of HS, all patients should follow basic therapeutic measures, including self-education about the disease, pain management, maintaining high hygiene standards, cessation of smoking, and losing weight, amongst others [1,96].”
Backgroundvan der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10254.x · Cited by 472 · cited 3×
“sion of NRLP3 as well as IL-1β were detected in HS lesions [75,77,78].”
Background
Cited by
Items 101–135 of 135
Hidradenitis suppurativa: latest insights on the etiology, pathogenesis and features of therapy
Svechnikova, E. V. S., & Zhufina, S. Е. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-351
Daoud, M., Benhadou, F., Suppa, M., Sarkis, A.-S., Heudens, S., Desmarest, L., Njimi, H., Daxhelet, M., Nobile, L., Karama, J., et al. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-024-03675-w
“Follicular occlusion causes follicular dilation and infun-dibulum dissection, leading to bacterial component release and damage-associated molecular patterns into the dermis [7, 8].”
Hidradenitis Suppurativa Biomarkers
Patel, R. H., Pixley, J. N., Samman, L., & Feldman, S. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-66513-4_11
Zhu, Z., & Wang, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-02075-4
Garber, B., & Glauser, J. (2025) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-025-00317-x
Lai, X., Yang, Y., Zhang, H., Zhang, C., Wang, M., Chen, W., Wang, B., & Yan, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322565
“The imperative lies in the early identification of HS, timely intervention, and the improvement of HS patient’s quality of life [23].”
Cheng, A., Berry, A., Harrah, P. A., Lee, T., & Farley, V. G. (2025) · JAAD Case Reports · doi:10.1016/j.jdcr.2025.06.008
Suppurations chroniques : idrosadénite suppurative (maladie de Verneuil)
Gandolfi, S., Grolleau, J. ‐., Guena, B., Lupon, E. L., & Chaput, B. (2025) · EMC - Techniques chirurgicales - Chirurgie plastique reconstructrice et esthétique · doi:10.1016/s1286-9325(25)44064-3
Yang, G., Liu, X., Wú, Z., & Zhu, C. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.07.003
Aygar, G. T., Gönül, M., Yayla, E. N. S., Erdem, H. B., & Kartal, S. P. (2025) · Pediatric Dermatology · doi:10.1111/pde.70063
Mosha, N., Mremi, A., Mshana, J., Kini, L. C., Mavura, D. R., & Jemec, G. B. E. (2025) · Clinical Case Reports · doi:10.1002/ccr3.71176
Alrubaiaan, M. T., Almajed, A., Alghamdi, A. S., Najjar, R. H., Alagha, S., Alowairdhi, Y. A., Albrahim, L., & Sheikh, A. A. (2025) · Journal of Advanced Trends in Medical Research · doi:10.4103/atmr.atmr_126_25
Diode Laser Therapy as an Adjunct to Minimally Invasive Therapy for Hidradenitis SuppurativaPreprint
Gonzalez, A. G., Laskowski, T., Thiyagarajan, S. K., Garner, S., & Thea, P. (2026) · Research Square · doi:10.21203/rs.3.rs-8281560/v1
Suppurazioni croniche: idrosadenite suppurativa (malattia di Verneuil)
Gandolfi, S., Grolleau, J.-L., Guena, B., Lupon, E. L., & Chaput, B. (2025) · EMC - Tecniche Chirurgiche - Chirurgia Plastica¸ Ricostruttiva ed Estetica · doi:10.1016/s1769-6704(25)51131-2
Hidradenitis Suppurativa Education for General Practitioners: A Pilot Study
Willems, A., Smith, A. D., & McMeniman, E. (2025) · Australasian Journal of Dermatology · doi:10.1111/ajd.70037
Defects of Intrinsic and Innate Immunity: Receptors and Signaling Components
Niehues, T., Casanova, J., & Bustamante, J. C. (2025) · Springer eBooks · doi:10.1007/978-3-032-01547-1_7
Advancing the Management of Hidradenitis Suppurativa: Emerging Therapies and Current Best Practices
Patel, D., Johnson, G., & Roth, G. M. (2026) · Journal of the Dermatology Nurses’ Association · doi:10.1097/jdn.0000000000000859
Swiss S1 Guidelines for the Management of Hidradenitis Suppurativa
Kolios, A. G. A., Laffitte, E., Mainetti, C., Messina, F., Pünchera, J., Schiller, P. I., Anzengruber, F., Läuchli, S., Jafari, S. M. S., Reiprich, K., et al. (2026) · Dermatology · doi:10.1159/000550649
“Diagnosis of HS is usually made by clinical examination and consensus diagnostic criteria based on three categories with typical lesions, in typical locations, and chronicity [32] (see Table 2).”
The Relationship Between Blood Groups and Hidradenitis Suppurativa: A Retrospective Evaluation
Esen, M., Demirbaş, A., Diremsizoğlu, E., & Sula, B. (2026) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.1906407
Bimekizumab for refractory hidradenitis suppurativa and associated inflammatory arthropathies
Tolete, C., Tolete, R., Friedman, A., & Tjahjono, L. A. (2026) · JAAD Case Reports · doi:10.1016/j.jdcr.2026.03.025
Early biological therapy in hidradenitis suppurativa: A commentary
Scala, E., & Fania, L. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70282
Self-citationPatient Resources and Support Groups for HS
Sejdiu, Z., Morgenstern, A. R., & Brownstone, N. D. (2026) · Clinical Cases in Dermatology · doi:10.1007/978-3-032-15200-8_22
Hidradenitis suppurativa in primary care: From early recognition to modern management
Steenkamp, I., & Pillay, L. (2026) · South African Family Practice · doi:10.4102/safp.v68i1.6318
Bonilla, E. C., Pilar, X. V.-D., Rocha, S. B., Contreras, N. M., & Lemini-López, A. (2026) · Cureus · doi:10.7759/cureus.109546
“Molecular and transcriptomic studies have demonstrated activation of keratinocyte-, neutrophil, and T lymphocyte-mediated immune responses within HS lesions, further supporting the rationale for targeted immunomodulatory therapies [4,5].”
Supuraciones crónicas: hidradenitis supurativa (enfermedad de Verneuil)
Gandolfi, S., Grolleau, J. ‐., Guena, B., Lupon, E. L., & Chaput, B. (2026) · EMC - Cirugía Plástica Reparadora y Estética · doi:10.1016/s1634-2143(26)51751-5
Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data
Martora, F., Tommasino, N., Esposito, V., Brescia, C., & Megna, M. (2026) · Medicina · doi:10.3390/medicina62050952 · Cited by 1
“Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by persistent or recurring painful inflammatory nodules, abscesses and draining tunnels in the apocrine gland-rich areas of the body such as axillary, inguinal, genital or inframam-mary regions [1,2].”
Self-citationTekielak, A., Polak, K., Frątczak, A., & Bergler-Czop, B. S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124699
Hidradenitis suppurativa: epidemiology, diagnosis, molecular pathogenesis and therapy
Lolli, M. G., Sanna, L., Belli, R., Dattolo, A., Fania, L., Colonna, L., Marchetti, P., Albanesi, C., Mercurio, L., & Madonna, S. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00495-4
“Given an estimated global prevalence of around 1%, HS also has considerable socioeconomic relevance to society [3–5].”
Rutkowski, C., & Foy, V. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.148005
Serum Asprosin Levels in Patients with Hidradenitis Suppurativa: A Case–Control Study
Doğan, M., Çetinkaya, E., Canat, H. D., Gök, A. M., Yıldız, B., Türkoğlu, Z., & Yavuz, İ. H. (2026) · Diagnostics · doi:10.3390/diagnostics16162621
“Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that primarily affects the axillary, inguinal, perianal, and inframammary regions—areas rich in apoc-rine glands—and is characterized by painful nodules, abscesses, sinus tracts, and scar formation [1].”
InfluentialBlanco, C. C., Sánchez‐Gutiérrez, I., Díaz, R. R., González, P. F., Orta, A. S., Moya, A. I., Romero, C., & Roldán, F. A. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107562
Ye, Q., Li, Y., Zhang, C., Tang, X., Lai, X., Zhu, L., He, Y., Yan, Y., & Wang, B. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.09.025
Maas, K., Sharma, A., Kapur, S., Kaakarli, H., Tadrousse, K. S., Sidhu, K. S., Verma, K. K., Unver, L., & Burkhart, C. G. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-026-04984-y
“Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, inflammatory skin condition that significantly impacts patients’ quality of life [ 24 ].”
Hidradenitis suppurativa skin microbiome: In‐depth analysis and modulation by systemic therapies
Amar, Y., Baumann, D., Niedermeier, S., Silva, R. L., Walch, S., Schloter, M., Köberle, M., Biedermann, T., & Volz, T. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70813
Self-citationBlanco, C. C., Gutiérrez, I. S., Díaz, R. R., González, P. F., Orta, A. S., Moya, A. I., Romero, C., & Alfageme, F. (2026) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2026.107562
Metadata
- Authors
- Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., & Fabbrocini, G.
- Affiliations
- Karolinska Institutet (SE)
- University of Naples Federico II (IT)
- Division of Dermatology and Venereology, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden
- Technical University of Munich (DE)
- Karolinska University Hospital (SE)
- Corresponding author
- Scala, Emanuele
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-08-15
- Volume
- 10
- Issue
- 8
- Pages
- 2094
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC8392140
- OpenAlex
- W3195421093
- Semantic Scholar
- 304c292cd74070067b2680ed72014e3741c3c074
- Cited by
- 135
- References
- 152
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 31 · 2023: 27 · 2022: 20 · 2021: 2
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion, cc-by)
- Funders
- Technische Universität München
- Topics
- Health Sciences › Medicine › Dermatology › Hidradenitis Suppurativa and Treatments
- Health Sciences › Medicine › Dermatology › Autoimmune and Inflammatory Disorders
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- hidradenitis suppurativa, pathogenesis, follicular occlusion, apocrine glands, inflammatory cytokines, Th17 cells, Th22 cells, neutrophils, IL-17, TNF-α, IL-10, immune dysregulation, animal models, diagnosis, treatment, surgical treatment, chronic inflammatory skin disease
- MeSH terms
- Anti-Inflammatory Agents, Combined Modality Therapy, Humans, Inflammation, Skin, Biomarkers, Cytokines, Hidradenitis Suppurativa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.